Pamela Brodt
Acute Care · Springfield, ILNPI 1982737789
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,958 of the $8,127 with a category attached, or 85.6%. 7 manufacturers reported payments, led by Novo Nordisk at 49.4% of the total. Reporting peaked in 2021 at $7,781 and has fallen 99.8% since, to $18 in 2025. Among acute care clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $262.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Sanofi-aventis U.S. LLC$3K
- Abbott$186
- Bayer$160
- AstraZeneca$135
- Tandem Diabetes Care, Inc.$131
- plus $18 from 1 others
What the payments were for
- Speaking & faculty fees$6,95886%
- Food & beverage$1,16914%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $4,014 |
| Sanofi-aventis U.S. LLC | 6 | $3,483 |
| Abbott | 6 | $186 |
| Bayer | 2 | $160 |
| AstraZeneca | 2 | $135 |
| Tandem Diabetes Care, Inc. | 2 | $131 |
| BD | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$3,934
- SOLIQUA 100/33$2,208
- TOUJEO$1,275
- FARXIGA$109
- FREESTYLE LIBRE 3$109
- Kerendia$103
How this compares
$8,127 in reported general payments places this provider in the 95th percentile of 461 acute care providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $57,903 |
| Sertraline Hcl | 64 | $1,927 |
| Divalproex Sodium | 15 | $711 |
| Escitalopram Oxalate | 35 | $600 |
| Buspirone Hcl | 23 | $451 |
| Quetiapine Fumarate | 13 | $427 |
| Trazodone Hcl | 28 | $341 |
Paid to pharmacies, not to this prescriber.
Other acute care in Springfield
- Tedra GrayChicago$78K
- Lynn HickmanArlington Heights$61K
- Gwen CassidyChicago$46K
- Laura CoyleOak Lawn$34K
- Erin DarguzasChicago$17K
- Amy BatesQuincy$14K
- Sarah MiyataChicago$11K
- Katie MeadorChicago$10K
- Dena PelletreauArlington Heights$9K
- Pamela KontosHazel Crest$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.